Biocomposite materials comprising probiotics, collagen and bacterial exopolysaccharides and uses thereof
By using collagen matrix to protect probiotics in the treatment of bacterial vaginitis, forming biological composite materials, the recurrence and antibiotic resistance problems in BV treatment are solved, and the pH value of vaginal fluid is restored and the stability and stickiness of probiotics are achieved. Improved adhesion provides an effective non-antibiotic treatment plan.
Patent Information
- Application Number
- CN202180021872.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-16
- Filing Date
- 2021-03-15
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2041-03-15
AI Technical Summary
Existing treatments for bacterial vaginitis (BV) have recurrence problems and the challenges of antibiotic resistance. Traditional antibiotic treatments cannot effectively solve the disease in the long term, and the adhesion and proliferation efficiency of probiotic treatments lead to a high risk of recurrence.
Using a new strategy based on biocompatible collagen matrix to protect probiotics, the formation of biocomposite materials is enhanced by combining Lactobacillus fermentation (L.fermentum) and Lactobacillus acidophilus) with collagen and extracellular polysaccharides to form biocomposite materials and enhance resistance. Cure properties of BV infection ensure the localization and proliferation of probiotics in damaged vaginal fluid.
This method can effectively restore the pH value of damaged vaginal fluid to a healthy state, improve the stability and adhesion of probiotics, reduce the risk of BV recurrence, and provide a long-term treatment plan for non-antibiotics.
Smart Images

Figure HDA0003848950540000011 
Figure HDA0003848950540000021 
Figure HDA0003848950540000031
Abstract
Description
Technical Field
[0001] The present invention relates to the field of therapeutics and more particularly to the treatment of bacterial vaginosis using a probiotic composition forming part of a biocomposite material. Background Art
[0002] Bacterial vaginosis (BV) is the most common cause of vaginal disease in women of childbearing age. The most common symptoms of this infection are dense, abnormal vaginal discharge, pain, itching and unpleasant odor. Independent studies have confirmed that BV increases the risk of other diseases, such as pelvic inflammatory disease and sexually transmitted infections (STIs), including human immunodeficiency virus (HIV). In addition, BV is strongly associated with premature birth and postpartum uterine infection.
[0003] From a microbiological perspective, BV is characterized by an alteration in the normal balance of the vaginal microbiota, a pathological condition often referred to as "vaginal dysbiosis." The natural microbiota helps create a protective barrier for the vaginal mucosa that prevents infection. However, the healthy microbiota is sensitive to multiple factors, particularly changes in mucosal pH, which can unbalance the microbial population in favor of the emergence of infectious microorganisms. The health of the vaginal microbiota is thought to be maintained by lactic acid bacteria such as Lactobacilli. Due to small imbalances in the pH of vaginal fluid (e.g., pH values ranging from 4 to 5 in healthy versus unhealthy environments), these lactobacilli are suppressed by the overgrowth of pathogenic bacteria such as Haemophilus vaginalis and Mobiluncus spp., which are present in small populations in health, leading to BV in women of childbearing age.
[0004] From a chemical point of view, the vaginal environment of healthy women is mainly controlled by lactic acid, the main metabolite of the lactic acid bacteria family. The concentration of other short-chain fatty acids (SCFAs) such as acetate, propionate and butyrate, which are associated with other typical harmful bacteria, is almost 100 times lower. Therefore, the pH is regulated by lactic acid (pKa = 3.80), which is present in a concentration of about 120 mM in healthy vaginal fluid, forming a pH of about 4. The reduction in the number of lactobacilli and the overgrowth of pathogenic bacteria change the metabolic pattern: SCFA increase, and the lactate concentration drops sharply, reaching about 20 mM. In particular, the concentration of acetate, the main component of SCFA, can reach about 120 mM from the initial 2 mM, which leads to an increase in pH to 5, because the pKa of acetate (4.86) is higher than that of lactate. Therefore, the pH of vaginal fluid changes from 4 (healthy) to 5 (BV), and the disease worsens over time. In fact, pH changes are a key parameter for diagnosing BV. For example, when the pH of vaginal fluid is higher than 4.5, the Amsel method diagnoses BV.
[0005] Traditional treatment for BV is antibiotics, especially metronidazole. However, several shortcomings of existing treatment modalities require the development of new therapeutic avenues. First, antibiotic-based treatments cannot avoid relapses. Second, the development of antibiotic-resistant bacteria due to overuse of antibiotics remains the greatest challenge facing modern medicine. Therefore, there is an urgent need for more effective long-term treatments that reduce our reliance on antibiotics.
[0006] Given the biochemical cycle that occurs during BV, whereby a decrease in lactic acid concentration ultimately promotes overgrowth of pathogens, one of the potential therapeutic strategies for BV may be to apply lactic acid directly to the infected vagina. While this treatment can alleviate symptoms, frequent and long-term use of this treatment is expected to avoid the recurrence of BV. Recent approaches have considered the use of probiotics from the Lactobacillus family. For example, WO2014184643 describes a composition that has antibacterial activity against bacteria that cause vaginitis and contains probiotics from the Lactobacillus family. Although promising, the efficiency of this approach will depend on the level of adhesion and proliferation of probiotics within the BV-compromised microproliferation and subsequent treatment, which can lead to BV recurrence. Summary of the invention
[0007] The authors of the present invention have developed a new strategy for the treatment of BV based on the use of a biocompatible collagen matrix that protects probiotics and allows their effective localization and proliferation in damaged vaginal fluid. In particular, the inventors have shown that a collagen scaffold (colLagen scaffold, col) is able to protect two biofilm-producing probiotics of the genus Lactobacillus, namely Lactobacillus fermentum (L.fermentum, Lf) and Lactobacillus acidophilus (L.acidophilus, La), producing hybrid materials col-Lf and col-La with enhanced anti-BV infection healing properties, respectively. These two materials correspond to biocomplexes composed of collagen, probiotics and bacterial EPS (exopolysaccharides). col-Lf and col-La are able to restore the pH of damaged simulated BV fluid to a healthy state. These collagen-encapsulated probiotics have excellent stability, which, combined with high adhesion to the vaginal mucosa and the inherent biocompatibility of the collagen matrix, makes these materials very promising in non-antibiotic BV treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 , SEM micrographs of collagen fibers assembled in PBS (pH 7.4) in the absence (ab) and presence of probiotic Lf (cd), followed by incubation in MRS to produce col-Lf (ef). Arrows indicate EPS.
[0009] Figure 2, SEM micrographs of collagen fibers in the presence of probiotic La. Different magnifications: 26.60kx (a) and 95.63kx (b).
[0010] Figure 3 FTIR spectra (a) and TGA curves (b) of collagen (Col) and Col-Lf. The inset in (b) shows the corresponding derivative TGA curve (DTG curve). Both characterizations confirmed that the bacteria were effectively incorporated into the collagen scaffold. (c) X-ray diffraction patterns of col and col-Lf. q represents the scattering vector amplitude, q = 4πsinθ / λ, θ is the scattering angle, and λ is the wavelength of the X-ray beam.
[0011] Figure 4 , Confocal images of col-Lf stained with SYTO9 (green) and propidium iodide (red) dyes. a) yz sections show bacterial penetration and complete integration into the collagen matrix. b) 3D image (318.20x 318.20x 38μm3) showing how bacteria are specifically arranged along collagen fibers (arrows). c) Higher magnification images show very few dead (red) bacteria (the image is a maximum intensity projection at a depth of 6 microns).
[0012] Figure 5 , a) Time evolution of pH in 1 / 10 diluted MRS medium containing Lf or col-Lf after storage for two weeks, four weeks and eight weeks at 4°C. The pH change of fresh samples is also shown. The error of these values expressed as standard deviation is less than ± 0.2. b) Time evolution of POM reducing activity in 1 / 10 diluted MRS containing Lf or col-Lf after storage for two weeks, one month or two months at 4°C. The evolution of POM reducing activity of fresh samples is also shown. The error bars show the standard deviation.
[0013] Figure 6 , a) Time evolution of pH in 1 / 10 diluted MRS medium containing La or col-La after storage for two weeks, 1 month or 2 months at 4°C. The change in pH value of fresh samples is also shown. The errors expressed as standard deviations for these samples are all less than ± 0.2. b) Time evolution of POM reducing activity in 1 / 10 diluted MRS containing La or col-La after storage for two weeks, 1 month or 2 months at 4°C. The evolution of POM reducing activity of fresh samples is also shown. The error bars show the standard deviation.
[0014] Figure 7a) Schematic diagram of the adhesion experiment. b) Evaluation of the adhesion of Lf and col-Lf to immobilized mucin. The absorbance at 590 nm correlates with the number of bacteria adhering to mucin. Also included are the absorbance values of the control groups (mucin and mucin+col). Data are presented as mean ± SD (n=3). *p<0.01 and ***p<0 0.005.
[0015] Figure 8 a) Schematic diagram of the adhesion evaluation experiment. b) Evaluation of the adhesion of La and col-La to immobilized mucin. The absorbance at 590 nm is related to the number of bacteria adhering to mucin. The absorbance values of the control groups (mucin and mucin+col) are also included. Data are expressed as mean ± SD (n = 3). *p < 0.01 and ***p < 0 0.005.
[0016] Fig. 9 , evaluate the adhesion of Lf and col-Lf to immobilized porcine mucin. The absorbance at 590 nm is related to the number of bacteria adhering to mucin. Also included are the absorbance values at 590 nm for the control group (mucin and mucin+col). Results with or without blocking with BSA are shown. Error bars show standard deviation. Asterisks indicate significant differences in mucin adhesion (** is p<0.01, *** is p<1.005).
[0017] Fig.10 , pH evolution of col-Lf and col-La, Lf and La in simulated BV liquid (initial pH 5.0). The errors expressed as standard deviations were all less than ±0.06. DETAILED DESCRIPTION
[0018] Method for obtaining biocomplex
[0019] In a first aspect, the present invention relates to a method for preparing a biomaterial comprising collagen, probiotics and exopolysaccharides, wherein the method comprises:
[0020] i) contacting the probiotics with the collagen monomers,
[0021] ii) incubating the mixture obtained in step i) under conditions sufficient to allow the collagen monomers to self-assemble into collagen fibers, thereby obtaining collagen fibers containing embedded probiotics, and
[0022] iii) maintaining the collagen fibers obtained in step ii) containing embedded probiotics under conditions sufficient for the probiotics to form exopolysaccharides (EPS) until the EPS content in the biomaterial is at least 2% (w / w) calculated as sugars relative to the collagen content of the biomaterial.
[0023] In a first step, the method according to the invention consists in contacting a population of probiotic bacteria with collagen monomers.
[0024] As used herein, the term "probiotic group" or "probiotic composition" refers to a single or mixed culture of microorganisms that, when provided to a mammal (e.g., a human), beneficially affects the host. In some embodiments, the probiotic composition of the present invention comprises a single type of bacteria. In other embodiments, the probiotic composition comprises two or more bacteria, such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 500, 1000 or more bacteria. In one embodiment, the probiotic composition comprises no more than 20 kinds of bacteria, such as 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 bacteria. In an exemplary embodiment, the probiotic composition comprises 8 kinds of bacteria. In other exemplary embodiments, the probiotic composition comprises 9 kinds of bacteria. In other embodiments, the probiotic composition comprises or is administered in conjunction with a probiotic, as described herein.
[0025] In one embodiment, the probiotic bacterial population comprises at least one strain capable of producing biofilm.
[0026] As used herein, the term "biofilm" refers to the extracellular matrix on which microorganisms are dispersed and / or form colonies. Biofilms are generally composed of polysaccharides and other macromolecules. Strains capable of producing biofilms useful in the present invention can be identified by using an assay as described in Example 1, wherein the strains are grown in a collagen scaffold in a compatible medium scaffold and an increase in sugar content is detected. As described below, strains capable of forming biofilms are defined as strains that result in a sugar content of at least 2.5% (w / w), at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50% or more in the final material, given as a mass ratio (w / w) relative to the collagen content in the biocomposite. It will be appreciated that strains capable of producing biofilms can also be identified using SEM by detecting the formation of a network corresponding to EPS in the biomaterial.
[0027] Preferred bacterial genera for use as probiotic compositions in the methods of the present invention include Lactobacillus and Bifidobacterium.
[0028] The term "lactic acid bacteria" or "LAB" as used herein refers to any bacteria that can produce lactic acid or at least one of its derivatives (including but not limited to acetic acid or propionic acid) as the main metabolic end product of carbohydrate fermentation. Therefore, the term is intended to include propionic acid bacteria (PAB), which produces propionic acid as a carbohydrate fermentation product. The illustrative non-limiting examples of lactic acid bacteria are Aerococcus, Carnobacterium, Enterococcus, Oenococcus, Teragenococcus, Vagococcus and Weisella of the genus Streptococcus and Lactobacillusales.Typically, the lactic acid bacteria are selected from the group consisting of species of Leuconostoc spp., Lactococcus cremoris, Lactococcus lactis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus kefiri, Lactobacillus bifidus, Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus paracasei and Lactobacillus rhamnosus, Lactobacillus salivarius, Lactobacillus curvatus, Lactobacillus bulgaricus, Lactobacillus salivarius, Lactobacillus curvatus, Lactobacillus bulgaricus, Lactobacillus salivarius, Lactobacillus salivarius, Lactobacillus curvatus, Lactobacillus salivarius ... sakei, Lactobacillus reuteri, Lactobacillus fermentum, Lactobacillus farciminis, Lactobacillus Lactis, Lactobacillus delbreuckii, Lactobacillus pLantarum, Lactobacillus parapLantarum, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus johnsonii, and Lactobacillus jensenii.
[0029] In a preferred embodiment, lactic acid bacteria is the bacterium of the genus Lactobacillus. As used herein, the term "lactobacillus" refers to the genus described by taxonomy ID 1578 in the NCBI database. In a specific embodiment, lactic acid bacteria is selected from lactobacillus fermentum, lactobacillus gasseri, lactobacillus reuteri, rod-shaped lactobacillus (Lactobacillus coryniformis), lactobacillus casei, lactobacillus paracasei, lactobacillus plantarum, lactobacillus salivarius and lactobacillus bulgaricus. In a more preferred embodiment, lactic acid bacteria is lactobacillus fermentum. The term "lactobacillus fermentum (Lactobacillus fermentum)" or "fermented lactic acid bacteria (L.fermentum)" refers to a kind of lactobacillus described by taxonomy ID 1613 in the NCBI database.
[0030] Exemplary strains of Lactobacillus gasseri include those deposited with American Type Culture Collection (ATCC) accession numbers (ATCC No. 33323, ATCC No. 19992, ATCC No. 4484, ATCC No. 4479, ATCC No. 4481, ATCC No. 4483, ATCC No. 4480, ATCC No. 4962, ATCC No. 9857, ATCC No. 4963, ATCC No. 29601, ATCC No. 33323. An exemplary strain of Lactobacillus gasseri is Lactobacillus gasseri JPS. Lactobacillus casei is a species of Lactobacillus widely used in dairy fermentation. Exemplary strains of Lactobacillus casei include strains with ATCC accession number PTA-3945, which may also be referred to as Lactobacillus casei KE01 or Lactobacillus casei KE99. Lactobacillus casei PTA-39045 is described in U.S. Patents.Other exemplary strains include ATCC No. 393, ATCC No. 334, ATCC No. 4007, ATCC No. 39539, ATCC No. 27139, ATCC No. 4940, ATCC No. 39392, ATCC No. 4913, ATCC No. 4646, ATCC No. 15008, ATCC No. 334D-5, ATCC No.PTA-2662, ATCC No.55825, ATCC No.55826, ATCC No.55841, ATCC No.PTA-5149, ATCC No.7469, ATCC No.25598, ATCC No.27216, ATCC No.25599, ATCC No.25302, ATCC No.11582, ATCC No.11982, ATCC No.39595, ATCC No.25180, ATCC No.11578, ATCC No.9595, ATCC No.14435, ATCC No.12116, ATCC No.25303, ATCC No.13075, ATCC No.29599, ATCC No.27092, ATCC No.11981, ATCC No.27773, ATCC No.8530, ATCC No.49178, ATCC No.335, ATCC No.14957, ATCC No.7469a, ATCC No.HB-12558, ATCC No.HB-12560, ATCC No.HB-12559, ATCC No.15820, ATCC No.27792, ATCC No.25937, ATCC No.27092-B1, ATCC No.87074. Lactobacillus acidophilus is a naturally occurring lactobacillus species in the gastrointestinal tract of humans and animals and is part of the normal vaginal flora. Some strains of Lactobacillus acidophilus are used in the production of dairy products. Exemplary strains of Lactobacillus acidophilus include ATCC No. 4356, ATCC No. 3154, ATCC No. 53544, ATCC No. 53544, ATCC No. 43121, ATCC No. PTA-4482, ATCC No. 4796, ATCC No. 53546, ATCC No. 4355, ATCC No. 9224, ATCC No. 4357, ATCC No. 832, ATCC No. 4357D-5, ATCC No. PTA-6751, ATCC No. 6820.
[0031] In a preferred embodiment, the probiotic is Lactobacillus fermentum and / or Lactobacillus acidophilus. In a more specific embodiment, the probiotic forming part of the probiotic composition is Lactobacillus fermentum CECT5716, Lactobacillus acidophilus CETC903 or a combination of both.
[0032] Lactobacillus fermentum CECT5716 is a strain isolated from human breast milk, which has been disclosed in PCT application published as WO2004003235.
[0033] Lactobacillus acidophilus CECT903 is a strain isolated from humans and is available from Colección deCultivos Tipo is available free of charge (https: / / www.cect.org / vstrn.php?lan=es&cect=903).
[0034] As provided herein, the therapeutic compositions comprise or alternatively modulate colonization and / or engraftment of the following exemplary bacterial entities: Lactobacillus gasseri, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus crispatus, Lactobacillus jensenii, and, Bifidobacterium breve (B. breve), Bifidobacterium longum (B. longum), Bifidobacterium bifidum (B. bifidum), Bifidobacterium dentium (B. dentium).
[0035] As used herein, the term "Bifidobacterium" or "bifidobacterium" refers to the genus of bacteria described in the NCBI database with taxonomic ID 1678. Illustrative, non-limiting examples of suitable bifidobacteria are Bifidobacterium lactis, Bifidobacterium bifidium, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium catenulatum, Bifidobacterium pseudocatenulatum, Bifidobacterium adolescentis and Bifidobacterium angulatum. In a particular embodiment, the bacterium of the genus Bifidobacterium is selected from Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis and Bifidobacterium animalis.
[0036] In one embodiment, the probiotic composition comprises a single probiotic species. In another embodiment, when the probiotic composition comprises more than one probiotic species, the probiotic component does not comprise Lactobacillus plantarum strain LMG P-21021-LP01, Lactobacillus plantarum strain LMG P-21020-LP02, Lactobacillus fermentum strain DSM 26955 (LF15) or Lactobacillus fermentum strain DSM 26966 (LF16).
[0037] As used herein, the term collagen refers to a self-assembling biopolymer produced by reacting monomeric collagen in a neutral pH, slightly ionic solution.
[0038] The main monomer solution is a suitable aqueous solution or non-aqueous solution, depending on the monomer. In a preferred embodiment, the pH of the solution is controlled, and in a specific preferred embodiment, the solution is an aqueous solution, and the pH is buffered, preferably in the range of about 7.2 to about 7.6. Any buffer capable of maintaining the pH within this range is suitable; a preferred buffer is a phosphate buffer. The main monomer solution may include one or more additives in addition to the monomer. Additives may be selected to promote polymerization, to combine with the monomer to form a copolymer, or to provide a coating on the polymer structure. In embodiments where the polymer is collagen, preferred additives are glycosaminoglycans selected from one or more of hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratin sulfate, or proteoglycans selected from decorin, lumican, biglycan, keratocan, syndican, and mixtures thereof. Additives may be selected to change the physical properties of the monomer solution. For example, glycerol may be added to adjust the viscosity of the monomer solution. In other embodiments, a surfactant may be added to improve the wettability of the substrate.
[0039] The collagen construct can be an unoriented collagen gel, a tissue-derived collagen template or a nanostructure artificial template. Typically, the collagen construct includes a collagen selected from type I collagen, type N collagen and a mixture thereof. In a preferred embodiment, the collagen construct includes type I collagen. In other embodiments, the collagen construct includes a mixture of type I collagen and type N collagen. Preferably, the construct includes more type I collagen than type N collagen. In a preferred embodiment, the construct includes a mixture of about four parts of type I collagen to about one part of type N collagen. In some embodiments, the collagen construct can also include selected from type II collagen, type III collagen, type XI collagen, type IV collagen and a mixture thereof. The self-assembled collagen fibrils can be homotypic or heterotypic. In one embodiment, the collagen is type I collagen.
[0040] The collagen fibril matrix building block for building collagen compositions described herein can be obtained from a variety of sources, including, for example, pig skin. Suitable tissues containing collagen source materials that can be used as collagen separation or for preparing the collagen components of collagen compositions described herein include warm-blooded vertebrate submucosal layers or any other tissue containing extracellular matrix. Suitable methods for preparing submucosal layers are disclosed in U.S. Patent Nos. 4,902,508, 5,281,422, and 5,275,826, and their disclosures are all incorporated herein by reference. According to another embodiment disclosed herein, tissues containing extracellular matrix materials except submucosal tissue can be used to obtain collagen. The method for preparing tissues for obtaining purified collagen or partially purified extracellular matrix components by other extracellular matrix materials is known to those skilled in the art. For example, U.S. Pat. No. 5163955 (pericardial tissue); U.S. Pat. No. 5554389 (bladder submucosa), No. 099567 (gastric submucosa), No. 6576265 (generally extracellular matrix tissue), No. 6793939 (liver basement membrane tissue), 919,121 (liver basal tissue) and WO2001 / 45765 (generally extracellular matrix tissue), each of which is incorporated herein by reference. In various other embodiments, the collagen-containing source material can be selected from placental tissue, ovarian tissue, uterine tissue, animal tail tissue, skin tissue, bone, tendon and cartilage tissue. In some embodiments, collagen is selected from porcine skin collagen, bovine collagen and human collagen; however, according to the teachings of this article, any suitable tissue containing extracellular matrix is purified collagen or partially purified extracellular matrix. In this article, it will be understood and known that it can be used as a collagen-containing source material for separating matrix components. In one embodiment, the collagen is type I collagen isolated from horse tendon.
[0041] As mentioned above, one building block used to prepare the collagen fibril matrix is oligomeric collagen. The presence of oligomeric collagen allows the building blocks to self-assemble into the collagen fibril matrix, increasing the assembly speed, and the collagen composition has a clear fibril microstructure and excellent mechanical integrity (such as stiffness).
[0042] In some embodiments, the building blocks of the collagen fibril matrix also include non-oligomeric soluble collagen molecules of various proportions. In one embodiment, the building blocks include one or both of telopeptide collagen (telocollagen) and / or atelocollagen (atelocollagen). In certain embodiments, the building blocks include oligomeric collagen and atelocollagen. In other embodiments, the building blocks include oligomeric collagen and telopeptide collagen. In other embodiments, the building blocks include oligomeric collagen, telopeptide collagen and atelocollagen. The quantity of oligomeric collagen, telopeptide collagen, atelocollagen and / or other non-oligomeric soluble collagen molecules can be determined by synthetic collagen fibrils, which are determined by such as stiffness, strength, liquid and mass transfer, protein hydrolysis and / or compatibility. It can be prepared in solution before polymerization begins, to adjust one or more properties of the matrix. It should be understood that the predetermined ratio of oligomeric and non-oligomeric soluble collagen molecules for a specific active agent can be different from the ratio suitable for different active agents.
[0043] Collagen concentration can be expressed as mass / volume or mass / mass. Collagen content can be measured by any method known in the art, including but not limited to calibrated colorimetric determination, such as Sirius red (Sirius red) and amino acid analysis of hydroxyproline. The viscosity of collagen polymer preparations is affected by many factors, including but not limited to solution or dispersant / suspension, concentration, molecular composition, molecular size, temperature and operating conditions. Viscosity measurements can be obtained by any means known in the art, including but not limited to viscometers or rheometers.
[0044] The concentration of soluble collagen present in the composition in step (i) of the present invention can vary. In some embodiments, collagen is present in a concentration of about 0.5 mg / ml to about 500 mg / ml. In other embodiments, collagen is present in a concentration of about .05 mg / ml to about 100 mg / ml. In other embodiments, collagen is present in a concentration of about 0.1 mg / ml to about 100 mg / ml. In some embodiments, collagen is present in a concentration of about 0.2 mg / ml to about 50 mg / ml. In other embodiments, collagen is present in a concentration of about 0.3 mg / ml to about 40 mg / ml. In other embodiments, collagen is present in a concentration of about 0.4 mg / ml to about 30 mg / ml. In other embodiments, collagen is present in a concentration of about 0.5 mg / ml to about 20 mg / ml. In some embodiments, collagen is present in a concentration of about 0.6 mg / ml to about 10 mg / ml. In some embodiments, collagen is present in a concentration of about 0.7 mg / ml to about 8 mg / ml. In some embodiments, collagen is present in a concentration of about 0.8mg / ml to about 6mg / ml. In some embodiments, collagen is present in a concentration of about 0.9mg / ml to about 4mg / ml. In some embodiments, collagen is present in a concentration of about 1mg / ml to about 8mg / ml. In some embodiments, collagen is present in a concentration of about 1.1mg / ml to about 2mg / ml. In some embodiments, collagen is present in a concentration of about 1.2mg / ml to about 1.8mg / ml. In some embodiments, collagen is present in a concentration of about 1.3mg / ml to about 1.7mg / ml. In some embodiments, collagen is present in a concentration of about 1.4mg / ml to about 1.6mg / ml. In some embodiments, collagen is present in a concentration of about 1.5mg / ml.
[0045] The pH of the monomeric collagen solution used in step (i) is not particularly limited, as long as it is sufficiently acidic to prevent the collagen from spontaneously combining into fibers before step (ii) or before contacting with the probiotics. In one embodiment, the pH of the monomeric collagen solution is about 1 to 4. In a specific embodiment, the pH of the monomeric collagen solution is about 3 to 4. In one embodiment, the pH of the monomeric collagen is about 3.0.
[0046] In embodiments described herein, the synthetic collagen fibril matrix can have an oligomer content quantified by an average polymer molecular weight (AMW). As described herein, the adjustment of AMW depends on matrix polymerization kinetics, fibril microstructure, molecular properties and fibril structure, such as branching, pore size and mechanical integrity (e.g., matrix rigidity) between fibrils. In another embodiment, the oligomer content of the pre-matrix composition quantified by the average polymer molecular weight is positively correlated with matrix hardness.
[0047] In some embodiments, the non-oligomeric soluble collagen included in the composition used in step (i) is reduced collagen. As used herein, "reduced collagen" refers to collagen that has been reduced in vitro to remove or significantly reduce reactive aldehydes. For example, collagen can be reduced in vitro by treating the collagen with a reducing agent (e.g., sodium borohydride).
[0048] According to the teaching of the present invention, the purity of collagen fibril matrix is determined by SDS-PAGE, peptide map analysis, amino terminal sequence directly on collagen polymer or after specific enzyme (bacterial collagenase) or chemical (bromocyano) cleavage. Determination can be evaluated by any method known in the art, including but not limited to non-collagen impurity analysis. The method of characterizing collagen fibril matrix includes cation exchange HPLC, natural fluorescence, LC / MS, MS, dynamic light scattering, molecular sieve chromatography, viscosity measurement, circular dichroism, differential scanning calorimetry, trypsin method, including but not limited to sensitivity, impurity analysis, TEM, SEM, cryo-SEM, confocal microscope, scanning electron microscope, multiphoton microscope and atomic force microscope.
[0049] The ratio of probiotics to collagen in step (i) of the method according to the invention is not particularly limited, as long as the amount is sufficient so that after step (iii) of the invention, a sufficient number of probiotic microorganisms are found in the biocomposite to achieve the desired effect. In one embodiment, the probiotic population is mixed with collagen monomers at a ratio of about 10 mg of collagen per mg of collagen. 4 –10 14 In one embodiment, the probiotic population is contacted with the collagen monomer at a ratio of about 10 CFU per mg of collagen. 5 –10 13 In one embodiment, the probiotic population is contacted at a ratio of about 10 CFU per mg of collagen. 6 –10 12 In one embodiment, the probiotic population is contacted with the collagen monomer at a ratio of about 10 CFU per mg of collagen. 7 –10 11 In one embodiment, the probiotic population is contacted at a ratio of about 10 CFU per mg of collagen. 8 –10 10 In one embodiment, the probiotic population is contacted with the collagen monomer at a ratio of about 10 CFU per mg of collagen. 9 –10 10 The ratio of CFU probiotic microorganisms to the collagen monomers. In one embodiment, the probiotic population is about 6×10 per 1.0 mg of collagen. 9 The ratio of CFU probiotic microorganisms in contact with collagen monomers.
[0050] In step ii), the mixture obtained in step i) is cultured under conditions sufficient to allow the collagen monomers to self-assemble into collagen fibers, thereby obtaining collagen fibers containing embedded probiotics.
[0051] The polymerization kinetics can be adjusted by controlling parameters such as pH, temperature and monomer concentration. In various embodiments, the monomer concentration is as described above. In preferred embodiments, the parameters of solution flow rate, solution viscosity and substrate rotation speed are controlled. Typically, the solution formed in step (ii) has a pH of about 6 to 9, about 6.5 to 8.5, about 7 to 8, about 7.2 to 7.8, about 7.4 to 7.7 or about 7.6.
[0052] Typically, the parameters of solution flow rate, solution viscosity, and substrate rotation speed are controlled to produce a 1 s -1 Up to 500000s -1 The shear rate is preferably 10 s -1 To 10000s -1 In some embodiments, the solution flow is controlled at a constant rate of about 0.05 to about 1000 ml / min, preferably about 0.1 to about 100 ml / min. In other embodiments, the solution viscosity is controlled within the range of about 1 specific heat (MPa-sec). In one embodiment, the viscosity is about 10 specific heats.
[0053] Step (ii) of the method of the present invention is allowed to proceed for a predetermined time or under continuous monitoring until a sufficient percentage of the collagen monomers assemble into fibers. The structure formed in step (ii) is characterized using known methods to characterize the microstructural features of the collagen fibril matrix, including ambient or cryostage scanning electron microscopy, transmission electron microscopy, infrared spectroscopy (FTIR), and at the molecular scale by X-ray diffraction.
[0054] In one embodiment, step (ii) is allowed to proceed until the structure is formed, which has peaks at 1030 and 1078 cm when analyzed by FTIR. -1 The peaks are shown at 1650, 1550 and 1240 cm-1 corresponding to the CO stretch (ν(CO)) of the carbohydrate group and broad absorption bands centered at 1650, 1550 and 1240 cm-1 arising from amides I, II and III, respectively.
[0055] In one embodiment, step (ii) is allowed to proceed until a structure is formed that, when analyzed by thermogravimetric analysis (TGA), has a moisture loss between room temperature and 150° C. and a collagen decomposition between 230 and 600° C. Alternatively or additionally, the structure formed after step (ii) is characterized by a weight loss between 180 and 240° C. This applies to Col-Lf biocomposites produced by decomposition of Lf.
[0056] In one embodiment, step (ii) is allowed to proceed until a structure is formed which, when analyzed by x-ray diffraction analysis, corresponds to an average equatorial molecule-to-molecule separation (ie, the lateral spacing between molecules).
[0057] Tensile, compression and viscoelastic properties can be determined by rheometer or tensile testing. All these methods are known in the art. Collagen characteristics and methods for characterizing collagen characteristics are discussed in ASTM International F3089-14, 2014 West Conshohoken PA, the disclosure of which is incorporated herein by reference in its entirety. In some aspects of the invention, the synthetic collagen fibril matrix exhibits a stiffness of at least 5Pa. In another embodiment, the synthetic collagen fibril matrix exhibits a hardness between 5Pa and 100GPa. Stiffness may also be referred to as elastic or linear modulus.
[0058] In one embodiment, fibers are formed having a diameter between 10 and 900 nm, more preferably between 50 and 800 nm, even more preferably between 100 nm and 700 nm, further preferably between 150 and 600 nm, even more preferably between 200 and 500 nm.
[0059] In one embodiment, collagen fibrils are formed that display a 67 nm periodically interlaced D-type stripe pattern.
[0060] In one embodiment, step ii) of the process according to the invention is carried out under continuous stirring. Typically mechanical stirring is employed.
[0061] In step (iii), the collagen fibrils containing embedded probiotics obtained in step (ii) are maintained under conditions sufficient for the formation of extracellular polysaccharides (EPS) by the probiotics until the EPS content in the biomaterial is at least 2% (w / w) relative to the collagen content of the biomaterial measured by sugar content.
[0062] Generally, "conditions sufficient to form extracellular polysaccharides (EPS)" are conditions suitable for the proliferation of probiotics embedded in collagen fibers. This generally requires that the collagen fibers be maintained in a culture medium that is sufficient to grow the probiotics embedded in the collagen fibers. Suitable culture media for use in step (iii) include those capable of producing about 10 9cfu / mL of cell concentration. In a preferred embodiment, when the probiotic group contains lactic acid bacteria, the culture medium is Man, Rogosa and Sharpe (MRS) culture medium, Reinforced Clostridial Medium (RCM), M17 or Brain Liver Infusion (Brain Liver Infusion, BHI), HANK's culture medium, APT culture medium, LM17 culture medium, GM17 culture medium and Elliker culture medium. In other embodiments, when the probiotic group contains bifidobacterium, the culture medium used in step (iii) includes MRS, Tryptone Phytone Yeast (TPY), glucose blood liver (BL), Columbia (CLB), liver cysteine lactose (LCL), modified MRS (mMRS), modified MRS and blood (mMRS+blood), modified BL (mBL) containing blood, modified RCM (mRCM), RCPB, etc. A description of MRS medium and other media suitable for the cultivation of lactic acid bacteria and bifidobacteria can be found in Handbook of Culture Media for Food Microbiology, Vol. 34, edited by Janet EL Corry, GDW Curtis, Rosamund M. Baird.
[0063] Step (iii) is performed as needed until the sugar content in the biocomposite is at least 2% (w / w) relative to the collagen content. The sugar content, which reflects the EPS content in the biocomposite, is determined using any method known in the art to determine the total sugar content in the sample. In a preferred embodiment, the sugar content in the biocomposite is determined using the standard phenol-sulfuric acid method (DuBois, Ka et al., Anal. Chem. 1956, 28350). In one embodiment, step (iii) is allowed to continue until the sugar content in the biocomposite is at least 2.5% (w / w), at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at most 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50% or more, all of which are expressed in w / w relative to the collagen content in the biocomposite. It should be understood that the progress of step (iii) can also be monitored by SEM by detecting the formation of a network corresponding to the EPS in the biomaterial.
[0064] It will be appreciated that the method according to the invention produces a biomaterial in which a large number of probiotics embedded in the collagen scaffold remain viable. After step (iii) of the method of the invention, the probiotics "remain viable" referred to herein means that the probiotics can be cultured. Although this does not mean that every probiotic cell in the biomaterial obtained after step (iii) remains viable, it can be interpreted as a detectable number of probiotics that can be cultured.
[0065] In various embodiments, after step (iii), at least 100%, at least 99.9%, at least 99.8%, at least 99, 7%, at least 99.6%, at least 99.5%, at least 99.4%, at least 99.3%, at least 99.2%, at least 99.1%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60% or at least 50% of the probiotics in the material are viable at 25°C and 60% relative humidity for at least 6 months, such as at least 24 months, such as at least 20 months, such as at least 16 months, such as at least 12 months, such as at least 8 months, such as at least 5 months, such as at least 4 months, such as at least 1 month, such as at least 14 days, or such as from 14 days to 24 months, such as from 14 days to 16 months, such as from 14 days to 8 months, such as from 14 days to 4 months, such as from 14 days to 2 months, such as from 14 days to 1 month.
[0066] Any method known in the art for determining the viability of probiotic flora can be used to determine the content of active probiotics in a biomaterial, using electrochromic polyoxometalate (POM) (González, N. et al., Chem. Common. 2015, 51). Once reduced, POM exhibits an absorption band centered at 820 nm in the UV-visible spectrum.
[0067] Biocomplexes of the present invention
[0068] The authors of the present invention have found that the process as described above results in a biocomposite material which exhibits certain unexpected properties in terms of maintaining the viability of the probiotic bacteria contained therein, even after storage under harsh conditions.
[0069] Therefore, in another aspect, the present invention relates to a biomaterial obtainable by the method of the present invention.
[0070] In another aspect, the present invention relates to a biomaterial comprising a collagen scaffold, probiotics and extracellular polysaccharides (EPS). In one embodiment, the collagen scaffold comprises fibrils having a diameter between 100 and 500 nm. In another embodiment, the collagen scaffold comprises fibrils characterized by a 67 nm periodically staggered D-type stripe pattern. In another embodiment, the sugar content in the biomaterial is at least 2% (w / w) relative to the measured collagen content of the biomaterial.
[0071] The term "probiotic" has been explained in detail in the context of the preparation method of the biomaterial according to the present invention, and is used with the same meaning in the context of the biomaterial according to the present invention. In a preferred embodiment, the probiotic is a lactic acid bacterium, a bifidobacterium or a combination of the two. In a more preferred embodiment, the lactic acid bacterium is selected from Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus jensenii and Lactobacillus gasseri, or wherein the bifidobacterium is selected from Bifidobacterium breve, Bifidobacterium longum and Bifidobacterium tooth or any combination thereof. In a more preferred embodiment, the probiotic is Lactobacillus fermentum and / or Lactobacillus acidophilus, more specifically, Lactobacillus fermentum CECT5716 and / or Lactobacillus acidophilus CETC903 or a combination thereof.
[0072] In the biomaterial, a plurality of probiotics embedded in the collagen scaffold remain viable in various embodiments, at least 100%, at least 99.9%, at least 99.8%, at least 99.7%, at least 99.6%, at least 99.5%, at least 99.4%, at least 99.3%, at least 99.2%, at least 99.1%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, or at least 50% of the biomaterial. The probiotics can survive at 25°C and 60% relative humidity for at least 6 months, such as at least 24 months, such as at least 20 months, such as at least 16 months, such as at least 12 months, such as at least 8 months, such as at least 5 months, such as at least 4 months, such as at least 1 month, such as at least 14 days, or such as 14 days to 24 months, such as 14 days to 16 months, such as 14 days to 8 months, such as 14 days to 4 months, such as 14 days to 2 months, such as 14 days to 1 month.
[0073] The term "collagen scaffold" as used herein refers to a matrix formed by spontaneous aggregation of collagen monomers when placed in a slightly acidic, neutral or slightly alkaline medium. The term "collagen monomer" has been explained in detail in the above-mentioned method for obtaining a biocomposite and is also applicable to this example. In a preferred embodiment, the collagen scaffold is obtained from type I collagen.
[0074] The appropriate concentration of probiotics in the biocomplex is at least 6 × 10 per gram of collagen. 12 CFU.
[0075] In one embodiment, the collagen scaffold is characterized by having a peak intensity at about 1030 and 1080 cm when analyzed by FTIR. -1 The absorption bands of the carbohydrate groups are broad and are centered at 1650, 1550, and 1240 cm -2 In another embodiment, the collagen scaffold is characterized in that when analyzed by X-ray diffraction, it shows a wavelength of about q = 13.25 nm. -1 The broad peak centered at q = 5.46 nm -1 , resulting in d-spacings of 0.47 and 1.15 nm, respectively. In another embodiment, the collagen scaffold is characterized by water loss between room temperature and 150°C and collagen decomposition between 230 and 600°C when analyzed by thermogravimetric analysis.
[0076] The term "exopolysaccharide" as used herein refers to a high molecular weight natural polymer composed of sugar residues and secreted by microorganisms into their environment. Exopolysaccharides can be interchangeably referred to as exopolysaccharides (EPS). EPS establishes the functional and structural integrity of biofilms and is considered to be an essential component that determines the physicochemical properties of biofilms. EPS accounts for 50% to 90% of the total organic matter in biofilms. However, some exopolysaccharides also contain non-carbohydrate substituents (such as acetate, pyruvate, succinate and phosphate). Exemplary exopolysaccharides include, but are not limited to, ethanosan (Acetobacter xylinum), alginate (Azotobacter vinelandii), cellulose (Acetobacter xylinum), chitosan (Mucorales sp.), curdlan (Alcaligenes faecalis var. myxogenes), cyclosophorans (Agrobacterium sp., Rhizobium sp., and Xanthomonas sp.), dextran (Leuconostoc mesenteroides, Leuconostoc dextranicum, and Lactobacillus hilarii). hilgardii), emulsan (Acinetobacter calcoaceticus), galactoglucopolysaccharides (Achromobacter sp.), Agrobacterium radiobacter, Pseudomonas marginalis, Rhizobium sp.) and Zooglea sp), gellan gum (Aureomonas elodea and Sphingomonas paucimobilis), glucuronan (Sinorhizobium meliloti), N-acetylglucosamine (Staphylococcus epidermidis), N-acetyl-heparosan (Escherichia coli), hyaluronic acid (Streptococcus equi), indole-3-sulfate (indican) (Beijerinckia indica), kefir polysaccharide (Lactobacillus hilarii), shiitake polysaccharide (Lentinus elodes), levan (Alcaligenes viscosus, Zymomonas mobilis), mobilis), Bacillus subtilis), pullulan (Aureobasidium pullulans), scleroglucan (Sclerotium rolfsii, Sclerotium delfinii and Sclerotium glucanicum), schizophyllan (Schizophylum communie), stewartan (Pantoae stewartii subsp. Stewartiii), succinoglycan (Alcaligenes faecalis, Sinorhizobium alfalfa), xanthan gum (Xanthomonas campestris) and welan (Alcaligenes sp.).
[0077] Suitable EPS found in the biocomposite according to the present invention include any EPS produced by one or more probiotic strains forming the probiotic cell population. In the specific case where the probiotic cell population includes lactic acid bacteria (LAB), the EPS forming part of the biocomposite may be a homopolysaccharide (HoPS), a heteropolysaccharide (HePS) or a mixture thereof.
[0078] HoPS is composed of one type of constituent monosaccharides (D-pyranose glucose or D-fructofuranosyl), including but not limited to α-glucan, β-glucan and β-fructan, and HePS includes any one of D-glucose, D-galactose, L-rhamnose and N-acetylated monosaccharides selected from N-acetylglucosamine (GluNAc), N-acetylgalactosamine (GalNAc), fucose, glucuronic acid, glycerol and mannose.
[0079] In other embodiments, the EPS forming part of the biocomposite according to the invention comprises one or more HoPS as summarized in Table 2 of RuasMadiedo et al. (International Dairy Journal, 2002, 12, 163-171), comprising:
[0080] -α-D-glucans, including dextran, mutan, alternan,
[0081] -β-D-glucan,
[0082] - Fructans, including levan and inulin
[0083] -Galactose
[0084] HePS consists of a backbone of repeating subunits that are branched (at the C2, C3, C4 or C6 position) or unbranched and consist of three to eight monosaccharides, monosaccharide derivatives or substituted monosaccharides.
[0085] In some embodiments, the HoPS and HePS forming part of the biocomplex according to the invention include any of the molecules shown in Table 1 of deVuyst et al. (International Dairy Journal, 2001, 11687-707), the entire contents of which are incorporated herein by reference. These include HoPS and HePS, wherein the repeating units include glucose (Glc), GlcNAc (N-acetylglucosamine), galactose, (Gal), GalNAc (N-ethylgalactosamine), rhamnose (Rha) and fucose (Fuc) in different combinations, wherein the repeating units are trisaccharides, tetrasaccharides, pentasaccharides, hexasaccharides, pentasaccharides and octasaccharides.
[0086] In other embodiments, the HoPS and HePS forming part of the biocomplex according to the present invention include any of the molecules shown in Table 4 of Vaningelgem et al. (Applied and Environment Microbiology, 2004, 70: 900-912), the contents of which are incorporated herein by reference in their entirety. These include EPS composed of galactose and glucose (first group), galactose, glucose and rhamnose (second group), galactose, glucose and N-acetylgalactosamine (third group), cysteose, glucose, N-acetylgalactosamine and rhamnose (fourth group), galactose, glucose, N-acetylcysteosamine and rhamnose (fifth group) or galactose, glucose and N-acetylglucosamine (sixth group).
[0087] In other embodiments, the HePS forming part of the biocomposite according to the invention comprises a HePS having any of the repeating units summarized in Table 2 of RuasMadiedo et al. (International Dairy Journal, 2002, 12, 163-171), the contents of which are incorporated herein by reference.
[0088] In one embodiment, the EPS forming part of the biocomplex according to the invention is selected from the group consisting of dextran, levan, mutan, alternan, reuteran and inulin. In another embodiment, the EPS is dextran, levan or a combination thereof.
[0089] The content of EPS in the biocomposite of the present invention is not particularly limited. The content of EPS can be determined by measuring the sugar content in the biocomposite, wherein the biocomposite uses any method known in the art to measure the total sugar content in a sample. In some embodiments, the sugar content in the biocomposite can be at least 2%, at least 2.5%, at least 3%, at least 3.5%, at least 4%, at least 4.5%, at least 5%, at least 5.5%, at least 6%, at least 6.5%, at least 7%, at least 7.5%, at least 8%, at least 8.5%, at least 9%, at least 9.5%, at least 10%, at least 11%, at least 12%, at least 13%, at least 14%, at least 15%, at least 16%, at least 17%, at least 18%, at least 19%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50% or more, all of which refer to the mass ratio (w / w) relative to the collagen content in the biocomposite.
[0090] Medical uses and pharmaceutical compositions of the biocomplex of the present invention
[0091] The authors of the present invention have found that the biocomposite of the present invention can attach to porcine mucin, said adhesion being partially dependent on the presence of collagen in the solution. Furthermore, the biocomposite of the present invention was also able to restore the healthy state of the fluid present in the simulated bacterial vaginosis fluid by changing the pH value of 5 present in pathological conditions to a pH value of 4 corresponding to a healthy state. Without being bound by any theory, this change in pH is certainly due to lactic acid secreted by the probiotics, which is consistent with previous evidence that the bacteria remain active when embedded in a collagen matrix. Interestingly, the pH of the La with Lf and without collagen decreased much more slowly and did not reach the healthy pH value of 4.0.
[0092] Thus, in another aspect, the present invention relates to a biomaterial according to the present invention for use in medicine. In another embodiment, the present invention relates to a biomaterial or a biocomposite according to the present invention for use in the treatment of vaginal dysbacteriosis, preferably vaginal infection. In another aspect, the present invention relates to a method for treating or preventing vaginal dysbacteriosis, more preferably vaginal infection, in a subject, comprising administering a biomaterial or a biocomposite according to the present invention.
[0093] As used herein, "preventing" or "prevention" refers to any method in which a disease state does not occur as a result of the action of a method (e.g., administration of probiotics and / or prebiotics as described herein). In one aspect, it will be understood that prevention may also mean that the disease does not occur to the extent that it occurs in an untreated control. For example, the frequency of disease may be reduced by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% compared to an untreated control. Thus, prevention of a disease includes reducing the likelihood of a subject developing a disease relative to an untreated subject (e.g., a subject not receiving the probiotics and / or prebiotics described herein).
[0094] "Treatment," "treat," or "treating" refers to a method of reducing the effects of a disease or condition. Treatment may also refer to a method of reducing the disease or condition itself, not just the symptoms. Treatment may be any reduction in pre-treatment levels, and may be, but is not limited to, complete elimination of the disease, condition, or symptoms of a disease or condition. Thus, in the disclosed methods, "treating" may refer to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of a determined disease or disease progression. For example, a disclosed method for reducing the effects of a vaginal infection is considered treating if one or more symptoms of a disease in an infected subject are reduced by 10% compared to pre-treatment levels in the same subject or a control subject. Thus, the reduction may be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any reduction in between, compared to natural or control levels. It is to be understood and contemplated herein that "treating" does not necessarily refer to a cure of a disease or condition, but rather to an improvement in the outlook for a disease or condition, such as bacterial vaginosis.
[0095] The term "dysbiosis" or "dysbiosis condition" is defined as a state in which the microbiota exerts a deleterious effect through (a) qualitative and quantitative changes in the content or number of the microbiota itself, (b) changes in its metabolic activity, and / or (c) changes in its local distribution. Specifically, vaginal dysbiosis is defined as an abnormality from a healthy state. In this context, a healthy state is defined as a state of relatively low susceptibility to sexually transmitted diseases. It is generally believed that the activity of lactobacilli helps to maintain this low susceptibility by protecting the vaginal environment from pathogens through the production of lactic acid, which results in a low pH. Therefore, one of the characteristics of vaginal dysbiosis is the presence of a relatively high pH.
[0096] In one embodiment, the vaginal dysbiosis is a vaginal infection.
[0097] The term "vaginal infection" as used herein refers to a condition or disease caused by the unwanted growth of a pathogen in the vagina, selected from the group consisting of Candida glabrata, Candida parapsilosis, Candida krusei, Candida tropicalis, Gardnerella vaginalis, Trichomonas vaginalis, Neisseria gonorrhoeae, Escherichia coli, Herpes simplex and Hemophilus ducreyie. The term includes, but is not limited to, candidiasis, vaginitis, vulvovaginitis and bacterial vaginitis.
[0098] In one embodiment, the biomaterial used according to the invention is used to treat an infection selected from bacterial vaginitis, trichomonas vaginitis or candidiasis. In a further embodiment, the biomaterial used according to the invention is used to treat an infection caused by bacteria, yeast or protozoan parasites.
[0099] In one embodiment, the infection is caused by an overgrowth of yeast in the vulvovaginal area, in which case the composition according to the invention is used for a "vaginal yeast infection". Vaginal yeast infections are typically caused by an overgrowth of Candida yeasts, such as, but not limited to, the commensal organism Candida albicans. Other Candida species associated with vaginal yeast infections include, but are not limited to, Candida glabrata, Candida parapsilosis, Candida krusei, and Candida tropicalis. Vaginal yeast infections may be referred to as "vaginal candidiasis" or "candidal vaginitis". Vaginal yeast infections may also be caused by non-Candida yeasts, such as Trichosporon species, such as Trichosporon Beigeli and Saccharomyces cerevisiae. Symptoms of vaginal yeast infections are vaginal irritation, discharge, and intense itching of the vagina and vulva. As with BV, broad-spectrum antibiotics, spermicides, hormones, and other factors that are not yet fully understood may disrupt the normal flora, leading to vaginal yeast infections. Vaginal yeast infections are also common in immunocompromised subjects.
[0100] In another embodiment, the infection is bacterial vaginosis.
[0101] The term "bacterial vaginitis" (abbreviated as "BV") and similar terms should be broadly understood as changes in the vaginal flora composition of female subjects compared to a baseline, reference or "normal" vaginal flora composition. BV is not limited to a specific vaginal flora composition or any specific symptoms observed in a specific female subject or female subject population. The term "vaginitis" as defined herein includes vaginitis selected from bacterial vaginitis, fungal vaginitis or Trichomonas vaginitis, preferably, caused by Haemophilus vaginalis, Bacteroides fragilis, Trichomonas vaginalis, Candida albicans, Streptococcus agalactiae, Streptococcus aureus, Staphylococcus aureus, Neisseria gonorrhoeae, Escherichia coli, Enterobacter cloacae, Pseudomonas aeruginosa or Salmonella typhimurium, etc. In one embodiment, bacterial vaginosis is caused by an overgrowth of normal vaginal flora selected from Haemophilus vaginalis or Mobiluncus spp.
[0102] Provided herein is a method for using a probiotic vaginal preparation. For example, in some embodiments, a probiotic vaginal preparation is used to acidify or maintain the acidity of the vaginal environment. Therefore, a probiotic vaginal preparation can be used to regulate acidification methods, including increasing acidity, maintaining acidity, or reducing vaginal acidity or pH. In some embodiments, a probiotic vaginal preparation is used to establish or improve vaginal flora, for example, by increasing the level of lactobacilli in vaginal flora or reducing the level of yeast (such as Candida yeast). Probiotic vaginal preparations can also be used to treat, alleviate, prevent or reduce the possibility of urogenital tract infection or inflammatory conditions (including vaginitis, urinary tract infection, vaginal atrophy and postoperative inflammation) in a subject. For example, a probiotic vaginal preparation can be used to treat, alleviate, prevent or reduce the possibility of vaginitis or its symptoms (such as vaginal dryness, burning or itching) in a subject. In the context of the above method, vaginitis may be a variety of causes, such as but not limited to BV, yeast infection or vaginal atrophy. Vaginitis or symptoms associated with vaginitis or similar to vaginitis may also be unknown causes. In another embodiment, the probiotic vaginal preparation can be used in a method for treating, alleviating, preventing or reducing the likelihood of vaginal dryness of various causes, such as, but not limited to, BV, yeast infection, trauma, drug side effects, or vaginal atrophy. In another embodiment, the probiotic vaginal preparation can be used in a method for treating, alleviating, preventing or reducing the likelihood of urogenital tract inflammation, including vulvovaginal inflammation of various causes, such as, but not limited to, infection, irritation, trauma, such as post-operative or childbirth trauma. One or more uses of the probiotic vaginal preparation can be described as being suitable for improving, maintaining, or achieving vaginal health.
[0103] The process or method of using a probiotic vaginal preparation includes the step of administering a probiotic vaginal preparation to a subject in an effective amount. The effective amount may vary according to the desired effect, specific formulation, dosage form, dosing regimen, and other factors. For example, a preparation in a capsule unit dosage form may be administered in an amount of 1-5 capsules per day, including, for example, 1 or 2 capsules per day. The administration period may be at least 1 day, at least 3 days, at least 6 days, or as prescribed by a doctor, or until the symptoms are improved or alleviated.
[0104] The method of treatment according to the present invention comprises administering a therapeutically effective amount of the biomaterial or probiotic biocomplex of the present invention to a subject in need thereof.
[0105] The term "effective therapeutic amount" as used herein refers to a sufficient amount of the bacteria or culture of the present invention to provide the desired effect, which is generally determined by factors such as the characteristics of the bacteria or culture of the present invention itself and the therapeutic effect to be achieved. It will also depend on the subject to be treated, the severity of the disease suffered by the subject, the dosage form selected, etc. Therefore, the dosages mentioned in the present invention must be regarded only as a guide for those skilled in the art, who must adjust the dosage according to the above variables. In one embodiment, the effective amount results in an improvement in one or more symptoms of the disease being treated, for example, normalization of the level of metals that are deficient in the subject.
[0106] The term "subject" is used herein to describe a human or animal. In the embodiments of the present product, formulation and method, "subject" refers to a female mammal, such as a human, to which the composition is administered vaginally. A female subject may suffer from or may suffer from a disease or condition, such as a urogenital tract infection, such as vaginitis. For example, a female subject may have a risk of recurrent urogenital tract infection or vaginitis due to her medical history, antibiotic use, spermicide use, or lifestyle (e.g., sexual habits). A female subject may also have or wish to prevent urogenital tract infection or vaginitis or its symptoms, suspected urogenital tract infection or suspected vaginitis, and urogenital tract similar infection or vaginitis-like symptoms, even without a formal diagnosis or full-blown urogenital tract infection or vaginitis.
[0107] In order to administer the biomaterial or biocomposite of the present invention, it must be formulated into a product suitable for vaginal administration, i.e. a vaginal product or vaginal preparation. Therefore, in another embodiment, the present invention relates to a pharmaceutical composition comprising a biomaterial according to the present invention and a pharmaceutically acceptable excipient suitable for vaginal administration.
[0108] The term "vaginal product" or "vaginal preparation" is used herein to refer to a composition of matter in a dosage form suitable for vaginal administration. The terms "vaginal probiotic product" and "vaginal probiotic preparation" refer to a composition of matter in a dosage form suitable for vaginal administration, including probiotics. Some examples of vaginal preparations are suppositories (including but not limited to capsules and tablets), tampons, solutions, powders, ointments, creams, and aerosol foams.
[0109] The term "vaginal administration" includes "transvaginal administration", "intravaginal administration" and refers to a route of administration in which a substance, composition or formulation is applied into the vaginal cavity or vulvovaginal region or through the vagina to other parts of the urogenital tract.
[0110] The probiotic composition for topical application can be applied in the form of cream or ointment. Therefore, they ideally include oily substances derived from plants, oceans or animal sources. Suitable liquid oils include saturated, unsaturated or polyunsaturated oils. For example, unsaturated oils can be olive oil, corn oil, soybean oil, rapeseed oil, cottonseed oil, coconut oil, sesame oil, sunflower oil, borage seed oil, shiitake seed oil, heme seed oil, herring oil, cod liver oil, salmon oil, linseed oil, wheat germ oil, evening primrose oil or a mixture of any ratio thereof. These creams or ointments can further include polyunsaturated fatty acids. In one or more embodiments, the unsaturated fatty acids are selected from ω-3 and ω-6 fatty acids. Examples of such polyunsaturated fatty acids are linoleic acid and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It is known that such unsaturated fatty acids have skin conditioning effects, which contributes to the therapeutic benefits of the composition. Thus, the composition may comprise at least 6% of an oil selected from omega-3 oils, omega-6 oils and mixtures thereof. Essential oils are also available, which are also considered therapeutically active oils, containing molecules that are bioactive and that exert a therapeutic effect when applied topically, which can be envisioned to be synergistic with the beneficial effects of the probiotic mixture in the composition. Another class of therapeutically active oils includes liquid hydrophobic plant-derived oils, which are known to have therapeutic benefits when applied topically. Silicone oils may also be used, and are ideal due to their known skin protection and occlusive properties. Suitable silicone oils include non-volatile silicones, such as polyalkylsiloxanes, polyarylsiloxanes and polyethersiloxane copolymers, polydimethylsiloxanes (dimethylsiloxanes) and poly(dimethylsiloxane)-(phenylsiloxane) copolymers. These are selected from cyclic or linear polydimethylsiloxanes containing from about 3 to about 9, preferably from about 4 to about 5 silicon atoms. Volatile silicones such as cyclomethicone may also be used. Silicone oils are also considered therapeutically active oils because they have barrier and protective properties.
[0111] For vaginal application, the probiotic composition can be in the form of vaginal capsules or vaginal tablets. The term "capsule" refers to a hard shell pharmaceutical capsule. The capsule is composed of a body and a lid, and may include a filling formulation containing a probiotic composition. Capsules suitable for use according to the present invention include, but are not limited to, NPcapsCR' containing pullulan, karachi polysaccharide and potassium chloride available from Capsugel, and capsules described in U.S. Patent No. 8105625 and U.S. Patent Application Publication No. 2005 / 0249676, and the capsules used according to the present invention contain a molecular weight of about 50 to 500 kDa, 100 to 400 kDa, about 150 to 300 kDa and preferably about 180 to 250 kDa. On the other hand, the capsule used according to the present invention contains about 50% to about 100% pullulan by weight (unfilled capsule). In other aspects, the capsule contains about 60% to 90% or 70% to 90% or 80% to 90% by weight of pullulan. Preferably, the capsule comprises about 85% to 90% pullulan by weight. The capsule used according to the present invention may further comprise (in addition to pullulan) one or more gelling agents (e.g., hydrocolloids or polysaccharides such as sodium alginate, agar gum, guar gum, locust bean gum, carrageenan, tara gum, gum arabic, pectin, xanthan gum, etc.); salts containing cations such as K, Li, Na, NH4, Ca, Mg; and / or surfactants such as sodium lauryl sulfate, sodium dioctyl sulfosuccinate, benzalkonium chloride, benzoyl chloride, hexadecyl trimethyl ester, fatty acid sugar esters, monoolein, polyoxyethylene sorbitan fatty acid esters, polyvinyl alcohol, dimethylpolysiloxane, sorbitan acid esters or lecithin.
[0112] The capsules used according to the present invention may further comprise one or more plasticizers (e.g., glycerol, propylene glycol, polyvinyl alcohol, sorbitol, maltitol, etc.); dissolution enhancers (e.g., maltose, lactose, sorbitol, mannitol, xylitol, maltitol, etc.); enhancers (e.g., polydextrose, cellulose, maltodextrin, gelatin, gum, etc.); in a preferred embodiment, the capsules comprise 85% to 90% by weight of pullulan, 1.0% to 1.5% of potassium chloride, 0.1% to 0.4% of carrageenan, one or more surfactants in an amount of 0.1% to 0.2% by weight, and 10% to 15% by weight of water.
[0113] The dosage form of probiotic vaginal probiotic preparation is suitable for vaginal administration and is selected to deliver an effective amount of vaginal probiotic preparation. In some embodiments, the probiotic vaginal preparation is provided in powder form and can be applied by a suitable applicator. In this case, the probiotic vaginal preparation can be provided as a component of a kit including an applicator. The probiotic vaginal preparation can be pre-packaged in an applicator or provided as a separate item of a kit. In some other embodiments, the probiotic vaginal application is incorporated into a vaginal tampon. The kit including a tampon optionally includes one or more applicators. Suitable dosage forms also include vaginal suppositories, including capsules and tablets, which can be applied with or without a suitable applicator. The selection of dosage form depends on a variety of factors. For example, the selected dosage form should ensure the stability of the formulation ingredients during storage, convenient administration, and rapid delivery of the formulation in the vaginal environment. In particular, the dosage form of the probiotic vaginal preparation should not adversely affect the activity or allow the premature (pre-administration) reconstruction of the probiotic ingredients of the formulation. For this reason, the dosage form should not contain water. At the same time, during administration, the dosage form should allow the formulation ingredients to be quickly dispersed or dissolved in the vaginal environment. For example, if a tablet or capsule is chosen as the dosage form, it should be formulated so that it disintegrates rapidly upon entry into the vagina.
[0114] Furthermore, administration may be chronic or intermittent as deemed appropriate by the supervising practitioner, particularly in view of any changes in disease state or any adverse side effects. "Chronic" administration refers to administration of the composition in a continuous manner, whereas "intermittent" administration refers to interruptions in treatment. The effective amount of colony forming units (CFU) of the strain in the composition will be determined by a person skilled in the art and will depend on the final formulation. For example, when administered orally in the absence of any other active agent, the total amount of the strain of the invention present in a single dose in the composition would, according to current legislation, be an effective daily dose of 10 7 -10 12 CFU, preferably 10 9 -10 11 CFU, and when administered vaginally or rectally, the amount is 10 3 Up to 10 12 CFU, preferably 10 5 Up to 10 10 The term "colony forming unit" ("CFU") is defined as the number of bacterial cells shown by microbial counts on an agar plate. Food supplements typically contain 10 7 Up to 10 12 In one embodiment, the composition of the present invention is a food supplement comprising 10 9 -10 11cfu / g. The term "drug product" has a broad meaning in this specification, including any composition comprising an active ingredient, in which case the strain of the present invention is preferably in the form of a composition, and a pharmaceutically acceptable excipient. The term "drug product" is not limited to drugs. The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions and / or dosage forms suitable for use in contact with tissues of a subject (e.g., a human) within the scope of reasonable medical judgment, without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio. Each carrier, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the preparation. Suitable carriers, excipients, etc. can be found in standard drug texts.
[0115] The present invention is defined by the following aspects:
[0116] ***
[0117] The present invention is explained below by means of the following examples, which are to be construed as merely illustrative and not limiting the scope of the present invention.
[0118] Example
[0119] Experimental Section
[0120] Reagents, bacterial sources, and collagen: High-purity reagents were purchased from Sigma-Aldrich. All solutions were prepared with ultrapure deionized water (18 MΩ·cm). Lactobacillus fermentum (Lf, CECT5716) powder was obtained from Biosearch Life SA. Lactobacillus acidophilus (La, CECT903, Moro 1900) was purchased from CECT (Colección de Cultivos Tipo). De Man Rogosa-Sharpe (MRS) medium was purchased from Thermo Scientific. Type I collagen was extracted from horse tendon using a standardized manufacturing method of OPOCRIN SpA (Corlo di Formine, Modena, Italy) as described by Tampieri, A. et al. (J. Biomed. Mater. Res., 2003, 67A, 618).
[0121] Embedment of Lactobacillus bacteria in collagen matrix: La and Lf were inoculated in 100 ml of MRS broth and cultured at 37°C with continuous stirring (180 rpm) for 24 h. Subsequently, the bacteria were collected by centrifugation (10000 g, 5 min), washed with physiological saline (0.9% NaCl aqueous solution), and resuspended in phosphate buffered saline (PBS, pH 7.4) to obtain a 2·10 9Colony forming unit (CFU) mL -1 Then, 3 ml of bacterial suspension was mixed with 1 mL of collagen solution (1.5 mg mL -1 , pH 3.0) to initiate the formation of a 3D matrix of self-assembled collagen fibers in the presence of probiotics. The collagen matrix containing embedded bacteria was maintained at 37°C for 30 minutes under continuous stirring (180 rpm), and then washed with 10 mL of physiological saline (0.9% NaCl aqueous solution) to remove unencapsulated bacteria.
[0122] Preparation of col-Lf and col-La biocomplexes: The collagen matrices containing embedded bacteria were then incubated in 10 mL of MRS broth for 6 h at 37°C. The resulting materials (referred to as col-Lf and col-La) were washed with saline and stored until further in vitro characterization.
[0123] In vitro characterization of col-Lf and col-La biocomplexes by field emission scanning electron microscopy (FESEM): Collagen matrices (with and without probiotics) as well as col-La and col-Lf biocomplexes were fixed in 1 mL of cacodylate buffer (0.1 M, pH 7.4) containing 2.5% glutaraldehyde at 4°C. After 24 h, the samples were washed three times with calcium carbonate buffer (30 min at 4°C). The samples were stained with osmium tetroxide solution (1% v / v) for 2 h in the dark and then repeatedly rinsed with Milli-Q water to remove excess osmium. The samples were then dehydrated with 50%, 70%, 90% and 100% (v / v) ethanol / water mixtures at room temperature for 20 min each, and the last concentration was repeated three times and dried at the CO2 critical point. Finally, the dehydrated samples were mounted on metal stubs using a conductive adhesive, covered with a thin carbon film, and analyzed using a FESEM (Zeiss Super40V, Centro de Instrución Scientifícica, University of Granada).
[0124] Ex situ characterization of col-Lf and col-La biocomplexes by Fourier-Transform Infrared (FTIR) spectroscopy: FTIR spectra were collected on a Bruker Tensor 27 spectrometer in attenuated total reflection (ATR) configuration by accumulating coverage from 4000–400 cm -1 100 scans of the spectral range with a resolution of 3 cm -1 .
[0125] The col-Lf and col-La biocomplexes were characterized in vitro by thermogravimetry analyses (TGA): TGA was performed using a Mettler–Toledo TGA / DSC1 thermobalance (Mettler–Toledo, Scientific Instrumentation Center, University of Granada) with a nitrogen flow of 5 °C / min up to 900 °C.
[0126] In vitro characterization of col-Lf and col-La biocomplexes by synchrotron X-ray diffraction: Data were collected on 1.0 mm diameter glass capillaries filled with dry collagen or collagen / bacterial matrix at the X04SA-MS beamline at the Paul Scherrer Institut (Villigen, Switzerland). The beam energy was set to 16 keV (operating wavelength, ). Data were collected with the aid of a position sensitive single photon counting MYTHEN II detector. Samples were freeze dried overnight at -40°C (LyoQuest, Telstar) prior to FTIR, TGA and X-ray diffraction characterization.
[0127] EPS quantification: The standard phenol-sulfuric acid method was used for EPS quantification (DuBois et al., Anal.Chem.1956, 28350). The sample was immersed in 1 mL of normal saline containing 500 μL of phenol (5% in water) and 2.5 mL of sulfuric acid and kept in a 30°C water bath for 20 minutes. The absorbance of each sample was measured at 490 nm. The EPS concentration was determined using the absorption coefficient obtained from the calibration curve and expressed in mg sugar / g collagen. A mixture of dextran and levulose was used for the calibration curve, which are the most characteristic components of EPS secreted by lactobacilli. Each sample was tested in triplicate.
[0128] In vitro viability assay: Following the manufacturer's instructions, use Baclight TMBacterial viability in Col-Lf was qualitatively assessed using a bacterial viability kit (Thermo Fisher). The assay involves combining a membrane-impermeant DNA-binding stain, propidium iodide (PI), with a membrane-permeant DNA-binding counterstain, SYTO9, to stain dead bacteria and live and dead bacteria, respectively. Confocal laser scanning microscopy (CSLM) images were acquired using a Nikon Eclipse Ti-EA1 microscope equipped with a 60× oil-immersion objective. Images were analyzed using NIS Elements software. To acquire SYTO 9 signals, a 488-nm laser and a 505–550-nm emission filter were used. For PI, a 561-nm laser and a 575-nm long-pass emission filter were used. Reconstructions of three-dimensional images were obtained using 39 z-sections.
[0129] Bacterial activity of col-Lf and col-La after storage at 4°C: Collagen-probiotic biocomplexes and corresponding controls (naked probiotics) were stored at 4°C for 2 weeks, 1 month and 2 months. After this time, the samples and controls were added to 10 mL of MRS broth medium, respectively, and incubated at 37°C and 180 rpm for 1 hour. Then, all samples were washed twice (3000 g, 5 minutes) with saline (0.9% NaCl aqueous solution). Subsequently, 10 mL of 1 / 10 diluted MRS broth medium was added and cultured at 37°C and 180 rpm. A 1 / 10 diluted MRS broth was used to avoid the autoreduction ability of non-diluted MRS broth. At predetermined times: 0, 2, 4, 6, 8 and 24 hours, 1 mL aliquots were collected from the supernatant of each culture in sequence.
[0130] Aliquots were centrifuged (3000 g, 5 min) to remove any residual bacteria. The fermentation activity of the encapsulated actives and corresponding controls was monitored by pH measurements. To confirm the enhanced viability of the collagen-bacteria system relative to non-encapsulated bacteria, we applied a procedure we developed that correlates bacterial proliferation with their response to electrochromic polyoxometalates (POMs) [P2Mo VI O62] 6-The reducing power of POM was correlated to (González et al., Chem. Common. 2015, 51). 190 μL of each aliquot was added to a well containing 10 μL of 10 mM POM solution. The samples were placed in the dark at room temperature. They were then irradiated with UV light (365 nm) for 10 minutes and the absorbance was measured in a Tecan nano-quantum plate reader. The same experiment was performed on materials stored at room temperature (fresh samples). In addition, a control of free col was used to confirm that the material itself could not reduce pH or reduce POM. Each aliquot was tested in triplicate.
[0131] In vitro assay for bacterial adhesion: Adhesion of col- and probiotics was determined according to previously reported methods with minor modifications [25,26]. Briefly, wells of Maxisorp plates (Nunc, Roskilde, Denmark) were incubated with 100 μL of 5 mg mL -1 Porcine mucin (Sigma-Aldrich) was incubated in PBS solution at pH 7.4 at 4°C overnight. After fixation, the wells were washed three times with PBS and blocked with 2% BSA in PBS for 1 hour. Bacterial pellets from 5 mL of bacterial culture fractions were collected by centrifugation (6000 g, 5 min), washed three times with PBS, and resuspended in 5 mL of PBS. After removing the BSA solution and washing the wells three times with PBS, bacterial suspension (100 μL, 108 CFU mL -1 For the collagen bacterial matrix sample, 25 μL collagen (50 mg mL -1 , 0.1M acetic acid solution). The plates were incubated with Lf or La on an orbital shaker at 180 rpm at 37°C for 2 hours. Non-adherent bacteria were removed by washing the wells three times with 100 μL PBS, and the samples were fixed at 60°C for 20 minutes. The fixed cells were then stained with crystal violet (100 μL per well, 0.1% solution) for 45 minutes at room temperature. Finally, the wells were washed twice with 150 μL PBS, and the stain bound to the bacteria was dissolved in 50 μL citrate buffer (pH 4.3) for 1 hour. The absorbance was measured at 590 nm using a microtiter plate reader (NanoQuant). After collecting four 50 μL replicates in one well, the results were expressed as the average of three samples with a total volume of 200 μL. The control group consisted of mucin and mucin collagen, with samples being mucin-Lf, mucin-La, mucin-col-La, and mucin-col-Lf, with or without BSA blocking.
[0132] Bacterial activity of col-Lf and col-La in simulated BV fluid: Collagen-probiotic samples and controls were added to 10 ml of simulated BV fluid respectively and cultured at 37°C and 180 rpm. One liter of BV fluid prepared according to a previously reported protocol (DHOwen, DFKatz, Contraception 1999, 59, 91) with slight modifications contained NaCl 3.51 g; KOH 1.40 g; Ca(OH)2 0.222 g; BSA 0.018 g; Urea 0.4 g; Glycerol 0.16 g; Glucose 10 g; Lactic acid 2 g; pH 5.00. At predetermined times: 0, 2, 4, 6, 8 and 24 hours, 1 mL aliquots were collected from the supernatant of each culture in sequence. The aliquots were centrifuged (3000 g, 5 minutes) to remove any residual bacteria. The pH of the embedded active materials and the corresponding controls was measured to demonstrate the ability to restore the pH of the culture medium. Each aliquot was tested in triplicate.
[0133] Statistical analysis: Results are expressed as mean ± standard error (SEM). Statistical comparisons were performed using GraphPad Prism software (version 6.0) using one-way ANOVA and Bonferroni's post hoc test. p < 0.05 was considered significant.
[0134] Example 1: Collagen matrix as probiotic scaffold
[0135] An acidic solution containing collagen monomers was mixed with probiotics (Lf or La) in PBS buffer (pH 7.4). The transient increase in pH caused the collagen to self-assemble into a high-density fibrous matrix with a length of several hundred micrometers and a diameter of 200 to 500 nm ( Figure 1 a, b), showing a typical D-type stripe pattern (67 nm). From the scanning electron microscope (SEM) micrograph ( Figure 1 cd) It can be seen that using this simple one-pot method, Lf( Figure 1 c, d) and La( Figure 2 ) probiotics were successfully entrapped into the collagen fiber network. Moreover, the presence of probiotics did not alter pH-induced collagen fiber structure and assembly, which was similar to that obtained in PBS without bacteria ( Figure 1 a, b).
[0136] Interestingly, when both probiotic-containing collagen materials were cultured in an optimal probiotic medium (such as MRS), the bacteria successfully proliferated and produced biofilms that modified the collagen fibers ( Figure 1ef and 2). Notably, these bacteria secrete exopolysaccharides (EPS). EPS plays an important role in biofilm formation, which is essential for the bacteria to create a microenvironment conducive to growth within the matrix (in this case, collagen fibers). Figure 1 The good integration of bacteria into the collagen matrix (evidenced by biofilm formation) is evident in Figure ef, showing how bacteria adhere to collagen fibers via their EPS ( Figure 1 f and Figure 2 These materials (col-Lf and col-La, hereafter referred to) are actually hybrid biocomposites consisting of three components: a collagen matrix, probiotics and their bacterial EPS, the latter acting as a natural "glue" for the other two components. Such biocomposites have never been reported before.
[0137] The amount of EPS in the biocomposites col-Lf and col-La was quantified by a standard sugar assay (see Experimental section). The values for col-Lf and col-La were 98 and 93.3 mg per gram of collagen, respectively. Interestingly, the initial material obtained by culturing probiotics and collagen in PBS contained much lower sugars (10 and 18.6 mg per gram of collagen, respectively). The sharp increase in sugars in the final biocomposites col-Lf and col-La is certainly attributed to biofilm formation in the optimal MRS medium, consistent with the SEM images.
[0138] The biocomplexes were characterized macroscopically by infrared spectroscopy (FTIR) and thermogravimetric analysis (TGA), and by synchrotron X-ray diffraction ( Figure 3 ) were further characterized at the molecular scale. FTIR spectroscopy and TGA of col-Lf revealed the fingerprint of collagen fibers, as well as some signals associated with the presence of bacteria ( Figure 3 a and b). The diffraction patterns of collagen and col-Lf are similar ( Figure 3 c), due to diffuse scattering of collagen fibers, with a wavelength of about q = 13.25 nm -1 A broad peak centered at q = 5.46 nm -1 The Bragg peak at 2.5 Å corresponds to the flat molecule-molecule average separation (i.e., intermolecular lateral spacing) of the collagen triple helix. This peak results in a d-spacing of 1.15 nm, which is very consistent with the corresponding d-spacing of collagen in dry non-mineralized biological tissue and confirms that bacteria do not affect the macromolecular assembly of collagen fibers.
[0139] A standard live / dead assay based on SYTO9 (green) / propidium iodide (red) showed that Lf and La bacteria were alive in col-Lf and col-La materials ( Figure 4 ).like Figure 4As shown, most of the Lf probiotics were still alive (green), and only a few dead bacteria were found (red). In addition, the side view image (sum of consecutive xy slices) ( Figure 4 a) shows that bacteria infiltrate and invade the entire collagen matrix, forming a unique hybrid biomaterial. Interestingly, the enlarged top view confocal image ( Figure 4 bc) shows the arrangement of bacteria along the collagen scaffold, indicating the specific recognition of probiotics by collagen. Similar results were found for col-La.
[0140] Example 2: Collagen matrix stabilizes probiotics and improves their metabolic activity under harsh conditions
[0141] The collagen matrix not only acts as a host scaffold for the probiotics, but also provides additional protection for the probiotics during storage under harsh conditions (e.g., at 4°C). Live bacteria secrete metabolites into the culture medium, especially lactic acid secreted by lactobacilli, which adjusts the pH value to around 4. We measured pH changes to monitor the metabolic activity of probiotics after storage under harsh conditions (4°C). The pH changes of fresh Lf and col-Lf (without heat treatment) and after storage at 4°C for two, four, and eight weeks are shown in Figure 2. Figure 5 As shown. The pH value of col-Lf induced dilution in MRS medium was higher than that of Lf ( Figure 5 a) showed a much lower pH drop, supporting that the probiotics embedded in the collagen matrix maintained their metabolic activity and probiotics. Similar behavior was observed for the col-La / La pair after two and four weeks of storage at 4°C. However, col-La stored for 8 weeks showed much lower activity ( Figure 6 a).
[0142] In addition, we evaluated the metabolic activity of col-Lf and col-La stored at 4°C using an electrochromic polyoxometalate (POM) assay that correlates the reducing capacity of the bacteria with their metabolic activity (González, N. et al., Chem. Common. 2015, 51). Once reduced, POM exhibits an absorption band centered at 820 nm in the UV-visible spectrum. The evolution of this absorption band was monitored after incubation of aliquots of the supernatant of col-Lf or Lf cultures with aqueous POM solutions ( Figure 5 b) POM reduction activity in MRS broth was enhanced when bacteria were embedded in a collagen matrix compared to free-stored bacteria ( Figure 5 b). Final values of col-Lf after two, four, and eight weeks of storage were similar to the results obtained for fresh samples (stored at room temperature). Similar behavior was observed for the col-La / La pair after two or eight weeks. The col-La sample after 2 months of storage showed a much smaller capacity to reduce POM ( Figure 6b), which is consistent with their poor ability to lower pH (see col-Lf) ( Figure 6 b) consistent.
[0143] These observations support that the collagen matrix helps maintain the core cellular activity of probiotics, especially Lf, even when exposed to long-term harsh storage conditions. Maintaining high metabolic and cellular activity is a key parameter for the successful use of probiotics in antibiotic-free therapy.
[0144] Example 3: Collagen matrix improves the adhesion of probiotics
[0145] Collagen is the main structural protein in the extracellular space of various connective tissues in the body. Therefore, another advantage of using collagen as a probiotic scaffold is the special ability of this protein to adhere to biological tissues. Adhesion of probiotics to the vaginal mucosa is essential for the effective treatment of BV with probiotics. In fact, if the biomaterial containing highly proliferating probiotics cannot adequately adhere to the vaginal mucosa, it will not provide much value for BV treatment.
[0146] We evaluated the adhesion properties of col-Lf / col-La and Lf / La to endothelial cells using porcine mucin, a material containing highly glycosylated proteins produced by epithelial tissues and a well-established adhesion model. The adhesion of col-Lf / col-La and Lf / La on immobilized porcine mucin was measured by indirect spectroscopic quantification of adsorbed bacteria labeled with crystal violet (see Experimental Section). Figure 7 As shown, col-Lf had significantly higher adhesion to mucin than Lf, supporting the ability of collagen to enhance adhesion of encapsulated probiotics. The col-La formulation also exhibited higher mucin adhesion than the La probiotic alone ( Figure 8 ). When comparing the adhesion of col-Lf and col-La to mucin, a higher signal corresponding to crystal violet was observed for col-Lf. This may be due to the higher CFU values of col-Lf compared to col-La as mentioned above.
[0147] Typical adhesion models also include treatment with bovine serum albumin (BSA) after mucin immobilization. After mucin immobilization, BSA blocks the remaining free sites on the protein-sensitive plate. Experiments using BSA ( Fig. 9 ) and not using BSA( Fig. 9 The corresponding experiment in b) showed no significant difference. This control experiment led us to conclude that the increase in absorbance was not due to potential adsorption of collagen to the protein-bound plate but rather to increased uptake by adherent col-Lf.
[0148] The higher adhesion of col probiotics to mucin compared to the original probiotics demonstrates the role of the collagen matrix, enabling the embedded probiotics to settle (nesting) in specific tissues, which may also be the case for the vaginal mucosa under pathogenic conditions caused by BV. As mentioned above, sufficient adhesion of the probiotic-containing material to the vaginal mucosa is crucial to achieve the effect of BV treatment. If adhesion is not optimal, the probiotics cannot effectively adapt and excrete lactic acid in the adverse microenvironment, and pathogenic bacteria may remain active, further promoting infection.
[0149] Example 4: col-Lf and col-La for BV treatment
[0150] The decisive step to confirm the functionality of col-Lf and col-La in BV treatment was their ability to restore healthy state from simulated BV fluid pH 5.0. Fig.10 As shown, both col-Lf and col-La were able to shift the pH of the BV medium from 5 to a healthy pH of 4. This pH shift was certainly due to lactic acid secreted by the probiotics, consistent with previous evidence that bacteria remain viable and active after being embedded in the collagen matrix. Interestingly, the pH drop with Lf and La without collagen was much slower and did not reach the healthy pH of 4.0 ( Fig.10 ).
[0151] Two observations worth highlighting from these results are: i) both materials, col-Lf and col-La, were able to shift the pH from unhealthy BV medium (pH 5) to healthy vaginal conditions (pH 4); and ii) the ability of col-Lf or col-La to reduce pH was higher than Lf or La. These observations suggest that the collagen matrix stabilizes the probiotics and makes them more robust to withstand impact in a harsh environment, like BV fluid. This is very important as it outlines the inefficiency of pristine probiotics as potential BV treatments and suggests the need for additional biocompatible matrices with high adhesion, such as collagen, that stabilize the probiotics to overcome the unfavorable BV medium.
Claims
1. A method for preparing a biomaterial comprising type I collagen, probiotics and exopolysaccharides, wherein the method comprises: i) contacting the probiotics with the collagen monomers, ii) incubating the mixture obtained in step i) under conditions sufficient to allow the collagen monomers to self-assemble into collagen fibers, thereby obtaining collagen fibers containing embedded probiotics, and iii) maintaining the collagen fibers obtained in step ii) containing embedded probiotics under conditions sufficient for the probiotics to form exopolysaccharides (EPS) until the EPS content in the biomaterial is at least 2% (w / w) relative to the collagen content of the biomaterial, the EPS content being measured as sugar content; The probiotics are lactobacillus or bifidobacterium.
2. The method according to claim 1, wherein step (ii) is carried out at a pH of 4 to 9.
3. The method according to claim 1, wherein step ii) is performed until collagen fibrils are formed, the diameter of the collagen fibrils being between 1 and 600 nm and / or showing a 67 nm periodically staggered D-type stripe pattern.
4. The method according to claim 1, wherein: Step ii) is carried out under continuous stirring.
5. The method according to claim 1, wherein step iii) is performed by incubating the collagen fibers containing embedded probiotics in MRS medium.
6. The method according to claim 1, wherein the probiotic is selected from the group consisting of Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus jensenii, and Lactobacillus gasseri, Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium denticulate.
7. The method according to claim 6, wherein the probiotic is Lactobacillus fermentum and / or Lactobacillus acidophilus.
8. The method according to claim 7, wherein the probiotics are Lactobacillus fermentum CECT5716 and / or Lactobacillus acidophilus CECT903.
9. A biomaterial obtained by the method according to any one of claims 1 to 8.
10. A biomaterial comprising a collagen scaffold, probiotics and extracellular polysaccharides (EPS), wherein the collagen scaffold comprises fibers with a diameter between 100 and 500 nm, and wherein the sugar content in the biomaterial is at least 2% (w / w) relative to the collagen content of the biomaterial, the probiotics are lactobacilli or bifidobacteria, and the collagen is type I collagen.
11. The biomaterial of claim 10, wherein the collagen scaffold comprises fibrils exhibiting a 67 nm periodic interlaced D-shaped stripe pattern.
12. The biomaterial according to claim 10, wherein the probiotic concentration is at least 6×10 12 CFU.
13. The biomaterial according to claim 10, wherein the EPS is selected from homopolysaccharides (HoPS) and / or heteropolysaccharides (HepS).
14. The biomaterial according to claim 13, wherein the HoPS is selected from α-glucan, β-glucan and β-fructan, and / or the HePS comprises any one of D-glucose, D-galactose, L-rhamnose and N-acetylated monosaccharides selected from N-acetylglucosamine (GluNAc), N-acetyl-galactosamine (GalNAc), fucose, glucuronic acid, glycerol and mannose.
15. The biomaterial according to claim 14, wherein the EPS is selected from the group consisting of dextran, levan, mutan, alternan, reuteran and inulin. The biomaterial according to claim 15 , wherein the EPS is dextran, levan or a combination thereof.
17. The biomaterial according to claim 10, wherein the lactobacillus is selected from the group consisting of Lactobacillus fermentum, Lactobacillus acidophilus, Lactobacillus crispatus, Lactobacillus jensenii and Lactobacillus gasseri, or wherein the bifidobacterium is selected from the group consisting of Bifidobacterium breve, Bifidobacterium longum and Bifidobacterium denticulate or any combination thereof.
18. The biomaterial according to claim 17, wherein the probiotic is Lactobacillus fermentum and / or Lactobacillus acidophilus.
19. The biomaterial according to claim 18, wherein the probiotic is Lactobacillus fermentum CECT5716 and / or Lactobacillus acidophilus CECT903 or a combination thereof.
20. Use of a biomaterial according to any one of claims 10 to 19 in the preparation of a medicament for the treatment of vaginal infections.
21. The use according to claim 20, wherein the infection is caused by bacteria, yeast or protozoan parasites.
22. The use according to claim 21, wherein the infection is bacterial vaginosis, Trichomonas vaginitis or candidiasis.
23. The use according to claim 22, wherein the infection is bacterial vaginosis.
24. The use according to claim 23, wherein the bacterial vaginosis is caused by an overgrowth of normal vaginal flora selected from the genus Haemophilus vaginalis or Bacillus mobilis.
25. A pharmaceutical composition comprising a biomaterial according to any one of claims 10 to 19 and a pharmaceutically acceptable excipient suitable for vaginal administration.
Citation Information
Patent Citations
Pullulan capsules
US20050249676A1
Tissue graft composition
US4902508A
Rapid assembly, concentric mating stent, tissue heart valve with enhanced clamping and tissue alignment
US5163955A
Fluidized intestinal submucosa and its use as an injectable tissue graft
US5275826A
Graft for promoting autogenous tissue growth
US5281422A
Cited By
Collagen-containing composite material and application thereof in preparation of corneal injury repair material
CN119524211A
